PHIO Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -- compared to Phio Pharmaceuticals Corp.'s net margin of --. Phio Pharmaceuticals Corp.'s return on equity of -95.19% beat Oragenics, Inc.'s return on equity of -509.23%.

Phio Pharmaceuticals Corp. has a consensus price target of $14.00, signalling upside risk potential of 968.7%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Phio Pharmaceuticals Corp. has higher upside potential than Oragenics, Inc., analysts believe Phio Pharmaceuticals Corp. is more attractive than Oragenics, Inc..

Phio Pharmaceuticals Corp. has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

Phio Pharmaceuticals Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals Corp. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

Phio Pharmaceuticals Corp. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Phio Pharmaceuticals Corp.'s net income of -$2.4M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Phio Pharmaceuticals Corp.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals Corp. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Phio Pharmaceuticals Corp.'s net margin of --. Phio Pharmaceuticals Corp.'s return on equity of -95.19% beat Palatin Technologies's return on equity of --.

Phio Pharmaceuticals Corp. has a consensus price target of $14.00, signalling upside risk potential of 968.7%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Phio Pharmaceuticals Corp., analysts believe Palatin Technologies is more attractive than Phio Pharmaceuticals Corp..

Phio Pharmaceuticals Corp. has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Phio Pharmaceuticals Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Phio Pharmaceuticals Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Phio Pharmaceuticals Corp.'s net income of -$2.4M is higher than Palatin Technologies's net income of --. Notably, Phio Pharmaceuticals Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals Corp. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Tharimmune, Inc. has a net margin of -- compared to Phio Pharmaceuticals Corp.'s net margin of --. Phio Pharmaceuticals Corp.'s return on equity of -95.19% beat Tharimmune, Inc.'s return on equity of -514.29%.

Phio Pharmaceuticals Corp. has a consensus price target of $14.00, signalling upside risk potential of 968.7%. On the other hand Tharimmune, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 109.21%. Given that Phio Pharmaceuticals Corp. has higher upside potential than Tharimmune, Inc., analysts believe Phio Pharmaceuticals Corp. is more attractive than Tharimmune, Inc..

Phio Pharmaceuticals Corp. has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Tharimmune, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Phio Pharmaceuticals Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tharimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals Corp. pays -- of its earnings as a dividend. Tharimmune, Inc. pays out -- of its earnings as a dividend.

Phio Pharmaceuticals Corp. quarterly revenues are --, which are smaller than Tharimmune, Inc. quarterly revenues of --. Phio Pharmaceuticals Corp.'s net income of -$2.4M is lower than Tharimmune, Inc.'s net income of -$2.1M. Notably, Phio Pharmaceuticals Corp.'s price-to-earnings ratio is -- while Tharimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals Corp. is -- versus -- for Tharimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -- compared to Phio Pharmaceuticals Corp.'s net margin of --. Phio Pharmaceuticals Corp.'s return on equity of -95.19% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Phio Pharmaceuticals Corp. has a consensus price target of $14.00, signalling upside risk potential of 968.7%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Phio Pharmaceuticals Corp., analysts believe Theriva Biologics, Inc. is more attractive than Phio Pharmaceuticals Corp..

Phio Pharmaceuticals Corp. has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Phio Pharmaceuticals Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phio Pharmaceuticals Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Phio Pharmaceuticals Corp. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Phio Pharmaceuticals Corp.'s net income of -$2.4M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Phio Pharmaceuticals Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phio Pharmaceuticals Corp. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.